Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1976 1
1977 1
1978 1
1983 1
1984 1
1986 2
1987 1
1989 2
1991 1
1992 1
1993 3
1994 5
1995 6
1996 5
1997 4
1998 4
1999 4
2000 4
2001 8
2002 9
2003 6
2004 15
2005 8
2006 16
2007 11
2008 12
2009 18
2010 14
2011 18
2012 27
2013 31
2014 33
2015 41
2016 33
2017 36
2018 26
2019 23
2020 10
2021 12
2022 18
2023 11
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Results by year

Filters applied: . Clear all
Page 1
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G Jr, Tsao AS, Heymach JV. Elamin YY, et al. Among authors: luthra r. Cancer Cell. 2022 Jul 11;40(7):754-767.e6. doi: 10.1016/j.ccell.2022.06.006. Cancer Cell. 2022. PMID: 35820397 Free PMC article. Clinical Trial.
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Borthakur G, et al. Among authors: luthra r. Am J Hematol. 2014 Oct;89(10):964-8. doi: 10.1002/ajh.23795. Epub 2014 Jul 21. Am J Hematol. 2014. PMID: 24990142 Free PMC article.
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Abaza Y, et al. Among authors: luthra r. Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21. Blood. 2017. PMID: 28003274 Free PMC article. Clinical Trial.
Medicinal Plants for Glioblastoma Treatment.
Datta S, Luthra R, Bharadvaja N. Datta S, et al. Among authors: luthra r. Anticancer Agents Med Chem. 2022;22(13):2367-2384. doi: 10.2174/1871520622666211221144739. Anticancer Agents Med Chem. 2022. PMID: 34939551 Review.
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Chihara D, et al. Among authors: luthra r. Br J Haematol. 2016 Sep;174(5):760-6. doi: 10.1111/bjh.14129. Epub 2016 Jun 15. Br J Haematol. 2016. PMID: 27301277 Free PMC article. Clinical Trial.
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Parra ER, et al. Among authors: luthra r. Clin Cancer Res. 2024 Apr 15;30(8):1655-1668. doi: 10.1158/1078-0432.CCR-23-0251. Clin Cancer Res. 2024. PMID: 38277235 Free PMC article.
Applications of CRISPR as a potential therapeutic.
Luthra R, Kaur S, Bhandari K. Luthra R, et al. Life Sci. 2021 Nov 1;284:119908. doi: 10.1016/j.lfs.2021.119908. Epub 2021 Aug 25. Life Sci. 2021. PMID: 34453943 Review.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Strati P, et al. Among authors: luthra r. Leuk Lymphoma. 2018 Jul;59(7):1672-1676. doi: 10.1080/10428194.2017.1397663. Epub 2017 Nov 9. Leuk Lymphoma. 2018. PMID: 29119847
432 results